Accent Therapeutics to Present Preclinical Data on Lead Clinical Program, ATX-295, at the 2026 American Association for Cancer Research Annual Meeting

B Findings reinforce the multi-tumor potential of KIF18A inhibitor, ATX-295, in high-grade serous ovarian, squamous non-small cell lung, and triple-negative breast cancer models LEXINGTON, Mass.,…
posteditor
posteditor
Articles: 16137

Other News